Immunicum

Immunicum AB (publ) develops cancer immunotherapies. The Company's two main groups of therapeutic cancer vaccines, SUBCUVAX™ and INTUVAX™, in addition to the method for expansion of tumor-specific T-cells (CD70), are based on the Nobel Prize awarded discovery of dendritic cells (DCs) and their central role in all immune responses. Since the raw material consists of white blood cells (DCs) from healthy donors, Immunicum's products can be mass-produced.

The therapeutic cancer vaccine INTUVAX™ is injected intratumorally and is currently being evaluated in a clinical Phase I/II-study in metastatic renal cell carcinoma. It utilizes each patient's own unique tumor tissue as antigen source and is thus a completely personalized therapeutic cancer vaccine that is still able to mass-produce and store in frozen condition for long periods of time.